Investment analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Moderna in a note issued to investors on Monday, January 13th. Brookline Capital Management ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on January 13 and set a price target of $40.00. The ...

We recently published a list of 11 Stocks That Will Go to the Moon According to Reddit. In this article, we are going to take ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

CytomX Therapeutics, a Bay Area biotech firm with lucrative and high-profile partnerships in the industry, is laying off 40% ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...